نتائج البحث - "Gasca-Ruchti, A"

1

Academic Journal

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

المؤلفون: Peters, S., Pujol, J.-L., Dafni, U., Dómine, M., Popat, S., Reck, M., Andrade, J., Becker, A., Moro-Sibilot, D., Curioni-Fontecedro, A., Molinier, O., Nackaerts, K., Insa Mollá, A., Gervais, R., López Vivanco, G., Madelaine, J., Mazieres, J., Faehling, M., Griesinger, F., Majem, M., González Larriba, J.L., Provencio Pulla, M., Vervita, K., Roschitzki-Voser, H., Ruepp, B., Mitchell, P., Stahel, R.A., Le Pechoux, C., De Ruysscher, D., Stahel, R., Hiltbrunner, A., Pardo-Contreras, M., Gasca-Ruchti, A., Giacomelli, N., Kammler, R., Marti, N., Pfister, R., Piguet, A.C., Roux, S., Troesch, S., Schneider, M., Schweri, R., Zigomo, I., Tsourti, Z., Zygoura, P., Tsouprou, S., Kassapian, M., Dimopoulou, G., Andriakopoulou, C.

المساهمون: Bristol-Myers Squibb Co Summit

المصدر: Annals of Oncology ; volume 33, issue 1, page 67-79 ; ISSN 0923-7534

الاتاحة: http://dx.doi.org/10.1016/j.annonc.2021.09.011
https://api.elsevier.com/content/article/PII:S0923753421044902?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0923753421044902?httpAccept=text/plain

View record in BASE

2

Academic Journal

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

المؤلفون: Soo, R.A., Han, J.-Y., Dafni, U., Cho, B.C., Yeo, C.M., Nadal, E., Carcereny, E., de Castro, J., Sala, M.A., Bernabé, R., Coate, L., Provencio Pulla, M., Garcia Campelo, R., Cuffe, S., Hashemi, S.M.S., Früh, M., Massuti, B., Garcia-Sanchez, J., Dómine, M., Majem, M., Sanchez-Torres, J.-M., Britschgi, C., Pless, M., Dimopoulou, G., Roschitzki-Voser, H., Ruepp, B., Rosell, R., Stahel, R.A., Peters, S., Stahel, Rolf, Peters, Solange, Soo, Ross, Han, Ji-Youn, Früh, Martin, Provencio, Mariano, Coate, Linda, Dafni, Urania, Hiltbrunner, Anita, Ruepp, Barbara, Roschitzki-Voser, Heidi, Gasca-Ruchti, Adriana, Giacomelli, Nino, Kammler, Rosita, Marti, Nesa, Nobs, Lionel, Pardo-Contreras, Mariana, Pfister, Rita, Piguet, Anne-Christine, Ribeli-Hofmann, Sabrina

المصدر: Annals of Oncology ; volume 33, issue 2, page 181-192 ; ISSN 0923-7534

الاتاحة: http://dx.doi.org/10.1016/j.annonc.2021.11.010
https://api.elsevier.com/content/article/PII:S0923753421048250?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0923753421048250?httpAccept=text/plain

View record in BASE

3

Academic Journal

Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC:Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)

المصدر: Peters , S , Felip , E , Dafni , U , Tufman , A , Guckenberger , M , Álvarez , R , Nadal , E , Becker , A , Vees , H , Pless , M , Martinez-Marti , A , Lambrecht , M , Andratschke , N , Tsourti , Z , Piguet , A-C , Roschitzki-Voser , H , Gasca-Ruchti , A , Vansteenkiste , J , Stahel , R A & de Ruysscher , D 2021 , ' Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage ....

الاتاحة: https://research.vumc.nl/en/publications/5cbb09d1-f28c-41dc-82db-7737694694e0
https://doi.org/10.1016/j.jtho.2020.10.129
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85099622666&origin=inward
https://www.ncbi.nlm.nih.gov/pubmed/33188912

View record in BASE

4

Academic Journal

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.

المصدر: Annals of oncology, vol. 31, no. 12, pp. 1734-1745

مصطلحات موضوعية: Immune-checkpoint inhibition, Malignant pleural mesothelioma, Pembrolizumab, Randomized clinical trial, randomised clinical trial

وصف الملف: application/pdf

Relation: info:eu-repo/semantics/altIdentifier/pmid/32976938; info:eu-repo/semantics/altIdentifier/eissn/1569-8041; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_0FC8052F26216; https://serval.unil.ch/notice/serval:BIB_0FC8052F2621; https://serval.unil.ch/resource/serval:BIB_0FC8052F2621.P001/REF.pdf

الاتاحة: https://serval.unil.ch/notice/serval:BIB_0FC8052F2621
https://doi.org/10.1016/j.annonc.2020.09.009
https://serval.unil.ch/resource/serval:BIB_0FC8052F2621.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_0FC8052F26216

View record in BASE

5

Academic Journal

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial

المؤلفون: Peters, Solange, Stahel, Rolf A., Dafni, Urania, Ponce Aix, Santiago, Massuti, Bartomeu, Gautschi, Oliver, Coate, Linda, Lopez Martin, Ana, van Heemst, Robbert, Berghmans, Thierry, Meldgaard, Peter, Cobo Dols, Manuel, Garde Noguera, Javier, Curioni-Fontecedro, Alessandra, Rauch, Daniel, Mark, Michael T., Cuffe, Sinead, Biesma, Bonne, van Henten, Arjen M. J., Juan Vidal, Oscar, Palmer Sanchez, Ramon, Villa Guzman, Jose Carlos, Collado Martin, Ricardo, Peralta, Sergio, Insa, Amelia, Summers, Yvonne, Lang, Istvan, Horgan, Anne, Ciardiello, Fortunato, de Hosson, Sander, Pieterman, Remge, Groen, Harry J. M., van den Berg, Paul M., Zielinski, Christoph C., Kuruvilla, Yojena Chittazhathu Kurian, Gasca-Ruchti, Adriana, Kassapian, Marie, Novell, Silvia, Torri, Valter, Tsourti, Zoi, Gregorc, Vanesa, Smit, Egbert F.

المصدر: Peters , S , Stahel , R A , Dafni , U , Ponce Aix , S , Massuti , B , Gautschi , O , Coate , L , Lopez Martin , A , van Heemst , R , Berghmans , T , Meldgaard , P , Cobo Dols , M , Garde Noguera , J , Curioni-Fontecedro , A , Rauch , D , Mark , M T , Cuffe , S , Biesma , B , van Henten , A M J , Juan Vidal , O , Palmer Sanchez , R , Villa Guzman , ....

مصطلحات موضوعية: NSCLC, Squamous, Erlotinib, Docetaxel, ETOP, VeriStrat, TYROSINE KINASE INHIBITORS, GROWTH-FACTOR RECEPTOR, 2ND-LINE TREATMENT, RETROSPECTIVE ANALYSIS, 3RD-LINE, THERAPY, METAANALYSIS, COMBINATION